School of Physiotherapy and Curtin Health Innovation Research Institute, Curtin University, Perth, Australia.
BMC Pulm Med. 2011 May 23;11:25. doi: 10.1186/1471-2466-11-25.
Advances in the understanding and management of pulmonary arterial hypertension have enabled earlier diagnosis and improved prognosis. However, despite best available therapy, symptoms of exertional dyspnoea and fatigue are commonly reported and result in a reduced capacity to perform daily activities and impaired quality of life. Exercise training has demonstrated efficacy in individuals with other respiratory and cardiovascular diseases. Historically, however, exercise training has not been utilised as a form of therapy in pulmonary arterial hypertension due to the perceived risk of sudden cardiac death and the theoretical possibility that exercise would lead to worsening pulmonary vascular haemodynamics and deterioration in right heart function. Now, with the advances in pharmaceutical management, determining the safety and benefits of exercise training in this population has become more relevant. Only three studies of supervised exercise training in pulmonary arterial hypertension have been published. These studies demonstrated improvements in exercise capacity and quality of life, in the absence of adverse events or clinical deterioration. However, these studies have not utilised an outpatient-based, whole body exercise training program, the most common format for exercise programs within Australia. It is uncertain whether this form of training is beneficial and capable of producing sustained benefits in exercise capacity and quality of life in this population.
DESIGN/METHODS: This randomised controlled trial will determine whether a 12 week, outpatient-based, supervised, whole body exercise training program, followed by a home-based exercise program, is safe and improves exercise capacity and quality of life in individuals with pulmonary arterial hypertension. This study aims to recruit 34 subjects who will be randomly allocated to the exercise group (supervised exercise training 3 times a week for 12 weeks, followed by 3 sessions per week of home exercise for 12 weeks) or the control group (usual medical care). Subjects will be assessed at baseline, 12 weeks and 24 weeks.
This study will determine whether outpatient-based, whole body exercise training is beneficial and safe in individuals with pulmonary arterial hypertension. Additionally, this study will contribute to clinical practice guidelines for this patient population.
Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12609000502235.
肺动脉高压的认识和治疗的进步使早期诊断和改善预后成为可能。然而,尽管有最佳的治疗方法,运动性呼吸困难和疲劳等症状还是经常被报告,并导致日常活动能力下降和生活质量受损。运动训练已被证明对其他呼吸系统和心血管疾病患者有效。然而,由于人们担心会突然发生心脏死亡,以及运动理论上可能导致肺血管血液动力学恶化和右心功能恶化,运动训练在肺动脉高压中并未被用作一种治疗形式。现在,随着药物治疗的进步,确定在该人群中进行运动训练的安全性和益处变得更加相关。只有三项关于肺动脉高压监督运动训练的研究已发表。这些研究表明,在没有不良事件或临床恶化的情况下,运动能力和生活质量得到了改善。然而,这些研究并未采用门诊全身运动训练方案,而这是澳大利亚最常见的运动项目形式。目前尚不确定这种形式的训练是否有益,是否能够使该人群的运动能力和生活质量持续得到改善。
设计/方法:这项随机对照试验将确定为期 12 周的门诊、监督、全身运动训练方案,随后进行家庭运动方案,是否安全,并改善肺动脉高压患者的运动能力和生活质量。本研究旨在招募 34 名受试者,他们将被随机分配到运动组(每周监督运动训练 3 次,共 12 周,随后每周进行 3 次家庭运动训练,共 12 周)或对照组(常规医疗)。受试者将在基线、12 周和 24 周进行评估。
这项研究将确定门诊全身运动训练对肺动脉高压患者是否有益且安全。此外,这项研究将为该患者人群的临床实践指南做出贡献。
澳大利亚和新西兰临床试验注册中心(ANZCTR):ACTRN12609000502235。